newsfilter
← Latest News
GlobeNewswire·

iTeos Reports First Quarter 2022 Financial Results and Provides Business Update

Enrolling patients with multiple myeloma in clinical trial of anti-TIGIT monoclonal antibody, EOS-448/GSK4428859A in monotherapy and in combination with BMS's novel CELMoD agent, iberdomide. Enrolling patients in the biomarker cohort in an ongoing clin